Profund Advisors LLC Has $297,000 Stock Position in CareDx, Inc. $CDNA

by · The Cerbat Gem

Profund Advisors LLC reduced its holdings in shares of CareDx, Inc. (NASDAQ:CDNA – Free Report) by 26.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,195 shares of the company’s stock after selling 5,422 shares during the quarter. Profund Advisors LLC’s holdings in CareDx were worth $297,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Acadian Asset Management LLC boosted its stake in shares of CareDx by 6.1% in the 1st quarter. Acadian Asset Management LLC now owns 359,303 shares of the company’s stock valued at $6,373,000 after purchasing an additional 20,806 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in shares of CareDx by 67.8% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 53,527 shares of the company’s stock valued at $950,000 after acquiring an additional 21,627 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in CareDx in the second quarter valued at about $352,000. Strs Ohio acquired a new stake in shares of CareDx during the first quarter valued at about $462,000. Finally, US Bancorp DE boosted its stake in shares of CareDx by 7.2% during the first quarter. US Bancorp DE now owns 18,403 shares of the company’s stock valued at $327,000 after purchasing an additional 1,235 shares in the last quarter.

CareDx Price Performance

Shares of CareDx stock opened at $15.94 on Friday. The firm has a market cap of $819.84 million, a price-to-earnings ratio of 15.63 and a beta of 2.50. The stock’s 50-day moving average is $14.82 and its 200 day moving average is $15.53. CareDx, Inc. has a one year low of $10.96 and a one year high of $26.37.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.15. The firm had revenue of $100.06 million for the quarter, compared to analyst estimates of $95.25 million. CareDx had a return on equity of 18.03% and a net margin of 17.97%.The company’s revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.14) earnings per share. CareDx has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CDNA shares. William Blair started coverage on shares of CareDx in a report on Tuesday, August 26th. They issued a “market perform” rating for the company. Wells Fargo & Company decreased their price target on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating for the company in a research report on Friday, August 8th. Craig Hallum cut their price target on shares of CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, July 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a research note on Thursday. Finally, Wall Street Zen raised CareDx from a “sell” rating to a “buy” rating in a research report on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, CareDx presently has an average rating of “Hold” and an average target price of $26.00.

View Our Latest Report on CDNA

CareDx Profile

(Free Report)

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Recommended Stories